Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Harry and Meghan surprised by King Charles' letter on their status
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Wall St slips as steep oil prices stoke inflation concerns ahead of CPI
- Qualcomm to issue warrant to Amazon for up to 25M shares
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Enanta Pharmaceuticals (ENTA) PT Lowered to $85 at RBC Capital
November 28, 2018 6:36 AM ESTRBC Capital analyst Brian Abrahams lowered the price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $85.00 (from $92.00) while maintaining a Sector Perform rating.
... MoreEnanta Pharma (ENTA) Tops Q4 EPS by 11c, Revenues Miss
November 26, 2018 4:02 PM ESTEnanta Pharma (NASDAQ: ENTA) reported Q4 EPS of $1.30, $0.11 better than the analyst estimate of $1.19. Revenue for the quarter came in at $67.2 million versus the consensus estimate of $68.52 million.
Enanta has never been in a stronger position from both a financial and clinical... More
